Residual cardiovascular risk associated with low levels of HDL was a major theme at the
American Heart Association's 2009 Scientific Sessions. The presentations on HDL biology …

The field of cardiovascular prevention has long anticipated the evolution of high-density
lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par …

The high-density lipoproteins (HDLs) are complex, polymolecular assemblies produced by
the jejunum, liver, in serum, and on the surface of macrophages. HDL cholesterol (HDL-C) …

Low density lipoproteins (LDL) and high density lipoproteins (HDL) are independent risk
factors for coronary heart disease (CHD); decreasing LDL-cholesterol (LDL-C) levels with …

High-density lipoproteins (HDLs) have captured the imagination of scientists and physicians
from virtually the time they were originally described, but especially after the cholesterol …

Our understanding of the in-vivo metabolism of HDL particles and their role in reverse
cholesterol transport is rapidly evolving, with long-standing concepts being constantly …

Current lipid management guidelines are focused on decreasing low-density lipoprotein
(LDL-C) levels as the primary target for reducing coronary heart disease (CHD) risk. Yet …

Five lines of evidence justify comprehensive lipoprotein management over aggressive low-
density lipoprotein (LDL) lowering alone in most cases of cardiovascular disease (CVD) …

Current US lipid-lowering guidelines indicate that optimal plasma levels of low-density
lipoprotein cholesterol (LDL-C) are< 100 mg/dL, and targeting global risk assessment has …